Our Pipeline
BRC’s R&D team is led by Dr. Hunter Land. An expert in the field of cannabinoid science, he has developed a pipeline of discovery work on over 20 novel cannabinoids and terpenes during his career.
BRC is developing phytocannabinoid-based treatments for the unmet medical needs of many.
Many patients are unable to tolerate existing treatment options.
Many patients are refractory or resistant to offered treatments.
Patients prefer
“natural therapeutics”.
There is a significant lack of effective and non-habit-forming pain medication.
BRC’s cannabinoid therapeutics are designed to have favorable drug profiles as partial, allosteric, or homeostatic regulators. Fewer off-target effects than many synthetic cannabinoids are expected, leading to improved safety profiles.
Clinical trials planned and upcoming
Autoimmune/inflammatory disease | Pain | Neurological diseases
We are committed to improving patient outcomes and providing support in compliance with federal and local regulations. We will consider the provision of cannabinoid active pharmaceutical ingredients as part of Investigator Initiated Trials. Please reach out directly to inquire.